Tsugawa, Koichiro
3 papers on CoChat
Most cited papers
- Verified
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 922
- Verified
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., et al. (2019) · British Journal of Cancer
Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery
Cited by 147
- Verified
Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
Iwata, H., Inoue, K., Kaneko, K., Ito, Y., Tsugawa, K., Hasegawa, A., Nakagawa, S., Kuratomi, H., & Tamura, K. (2019) · Japanese Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies
Cited by 46
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free